MOTIV Bioresorbable Scaffold in BTK Artery Disease

Inclusion Criteria: * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient presenting with rest pain or minor tissue loss (Rutherford classification from 4 to 5) * Patient is \>18 years old * Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study - Patient has a projected life-expectancy of at least 24-months * Patient is eligible for treatment with the MOTIV™ Bioresorbable Scaffold * Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure * De novo lesion or Restenotic lesion after PTA in the infrapopliteal arteries, suitable for endovascular therapy * Target vessel diameter visually estimated to be ≥2.5mm and ≤3.50mm * Guidewire and delivery system successfully traversed the lesion * Total target lesion is maximally 100mm * Definition of Target Lesion is: 1. short de novo or Restenotic lesion after PTA or 2. a short residual flow-limiting dissection or restenosis after PTA of a longer lesion Exclusion Criteria: * The reference segment diameter is not suitable for the available stent design * Untreated flow-limiting aortoiliac stenotic disease * Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment. * Any previous surgery in the target vessel * Aneurysm located at the target vessel * Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) * Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy. * Major distal amputation (above the transmetatarsal) in the study or non-study limb. * Septicemia or bacteremia * Any previously known coagulation disorder, including hypercoagulability * Contraindication to anticoagulation or antiplatelet therapy * Known allergies to scaffold or scaffold components * Known allergies to contrast media that cannot be adequately premedicated prior to the study procedure * Patient with known hypersensitivity to heparin-induced thrombocytopenia (HIT) type II * Currently participating in another clinical research trial